Duran, E. Et Al. 2023. Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritisanti-TNF. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , no.9 .

Duran, E., Yildirim, B. E. S., & KARADAĞ, Ö., (2023). Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritisanti-TNF. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , no.9.

Duran, E., B. E. S. Yildirim, And ÖMER KARADAĞ. "Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritisanti-TNF," CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , no.9, 2023

Duran, E. Et Al. "Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritisanti-TNF." CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , no.9, 2023

Duran, E. Yildirim, B. E. S. And KARADAĞ, Ö. (2023) . "Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritisanti-TNF." CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , no.9.

@article{article, author={E. Duran Et Al. }, title={Comment on: Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritisanti-TNF}, journal={CLINICAL AND EXPERIMENTAL RHEUMATOLOGY}, year=2023}